top of page

Geneovese

Abstract Blue Patterns

Our Vision

At Geneovese, we've identified a way to improve the stability, potency and tolerability of cell-targeted therapeutics using a new class of linker-payloads.

 

We're engineering a next generation payload architecture that improves stability and expands the therapeutic window. 

​

This could unlock indications that current ADCs can't reach, and unlock new treatment options for patients who have limited or ineffective treatment.  ​

Innovation

Cutting-Edge Solutions

Our technologies focus on the controlled release of cell-targeted therapeutics unlocking better tolerability, improved selectivity, modularity for quick iteration and innovation, and to address pressing global challenges in oncology.  By leveraging advanced methodologies, a deep understanding of therapeutic windows and interdisciplinary approaches, we aim to deliver the most efficacious solutions in the oncology space.​

Geneovese

​

We are a Delaware C-Corporation advancing the controlled release of cell-targeted therapeutics for patients with aggressive, underserved cancers.  We're evaluating high-value oncology indications where current ADCs underperform and where our platform has a clear mechanistic advantage.  A provisional patent assigns IP to the company, and the founder equity is structured for long-term alignment through completed 83(b) elections.  We currently operate with a lean, focused model by partnering with CROs. ​

Connecting Science and Innovation
bottom of page